CancerCareÂ® Announces Funding for Pancreatic Cancer Patients Through CancerCare Co-Payment Assistance Foundation (CCAF)
CancerCare, the leading national nonprofit organization providing free, professional support services to anyone affected by cancer, is pleased to announce the availability of co-payment assistance for pancreatic cancer patients through the CancerCare Co-Payment Assistance Foundation.
NEW YORK, NY (November 4, 2015) — CancerCare, the leading national nonprofit organization providing free, professional support services to anyone affected by cancer, is pleased to announce the availability of co-payment assistance for pancreatic cancer patients through the CancerCare Co-Payment Assistance Foundation.
The CancerCare Co-Payment Assistance Foundation (CCAF) is dedicated to helping people with cancer meet what otherwise are significant co-payment obligations for cancer treatment. CCAF is authorized to provide co-payment assistance for all types of cancer. This assistance is provided to ensure that patients have access to care and prescribed treatments.
People receiving assistance from CCAF also have immediate, ongoing access to the full array of CancerCare services, including counseling, support groups (online, telephone and in-person), resource referrals, publications, education and financial assistance with treatment-related expenses such as transportation and child care. The robust network of support services offered by CancerCare can have a significant impact on the patient, as well as the entire family.
“We are thrilled to provide this crucial co-payment assistance to people coping with a pancreatic cancer diagnosis,” said Patricia J. Goldsmith, CancerCare Chief Executive Officer. “Pancreatic cancer can be an especially challenging diagnosis to treat, and the CancerCare Co-Payment Assistance Foundation is committed to easing the financial burden so that patients can focus on managing their diagnosis and maintaining quality of life during treatment.”
An estimated 48,960 individuals will be newly diagnosed with pancreatic cancer by the end of 2015 (National Cancer Institute, 2015). This funding will enable CCAF to continue providing much-needed, comprehensive assistance to patients who are struggling to meet their coinsurance obligations, which may enable them to adhere to their prescribed treatments and potentially help to improve their outcomes.